DexCom, Inc.  

(Public, NASDAQ:DXCM)   Watch this stock  
Find more results for Eric S. Sayers
56.55
-0.30 (-0.53%)
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 56.28 - 57.20
52 week 28.09 - 58.32
Open 56.81
Vol / Avg. 706,613.00/730,299.00
Mkt cap 4.33B
P/E     -
Div/yield     -
EPS -0.36
Shares 76.56M
Beta 0.43
Inst. own 99%
Feb 18, 2015
Q4 2014 DexCom Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 10, 2014
DexCom Inc at Oppenheimer Healthcare Conference
Dec 2, 2014
DexCom Inc at Piper Jaffray Healthcare Conference
Nov 12, 2014
DexCom Inc at Credit Suisse Healthcare Conference
Nov 11, 2014
DexCom Inc at Stephens Fall Investment Conference
Nov 6, 2014
Q3 2014 DexCom Inc Earnings Call
Nov 6, 2014
Q3 2014 DexCom Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -7.54% -18.62%
Operating margin -7.25% -18.06%
EBITD margin - -13.69%
Return on average assets -13.95% -26.08%
Return on average equity -19.44% -37.00%
Employees 646 -
CDP Score - -

Address

6340 Sequence Drive
SAN DIEGO, CA 92121
United States - Map
+1-858-2000200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

DexCom, Inc. (DexCom) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The Company had received approval from the United States Food and Drug Administration (FDA) for its third generation system, the SEVEN PLUS, which is designed for up to seven days of continuous use. The SEVEN PLUS is indicated for use as an adjunctive device to complement, not replace, information obtained from standard home blood glucose monitoring devices. The enabling technologies for the Company�s sensors include biomaterials, membrane systems, electrochemistry and low power microelectronics.

Officers and directors

Jonathan T. Lord M.D. Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Terrance H. Gregg Executive Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Jess Roper Chief Financial Officer, Vice President
Age: 49
Bio & Compensation  - Reuters
Kevin R. Sayer President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Steven R. Pacelli Executive Vice President - Strategy and Corporate Development
Age: 42
Bio & Compensation  - Reuters
John D. Lister Senior Vice President, General Counsel
Age: 39
Bio & Compensation  - Reuters
Richard B. Doubleday Senior Vice President - Worldwide Sales and Marketing
Age: 51
Bio & Compensation  - Reuters
Andrew K. Balo Senior Vice President - Clinical and Regulatory Affairs
Age: 66
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jeffrey C. Moy Senior Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Jorge A. Valdes Chief Technical Officer
Age: 52
Bio & Compensation  - Reuters